跳至主要内容
临床试验/JPRN-UMIN000008557
JPRN-UMIN000008557已完成未知

Comparative study of Indium-111 labeled Pentetreotide (OctreoScan) as somatostatin scintigraphy and FDGPET for the imaging of neuroendocrine tumor and carcinoid tumor. - Diagnosis of neuroendocrine tumor using OctreoScan and FDGPET.

Department of Nuclear Medicine, National Center for Global Health and Medicine, Tokyo, Japan0 个研究点目标入组 30 人开始时间: 2012年8月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • •Patients having double cancer, or other serious diseases or condition cannot enter the study. Patients who need immediate surgical procedures or radiation therapy cannot enter the study. Pregnant patients cannot enter the study.

研究者

发起方
Department of Nuclear Medicine, National Center for Global Health and Medicine, Tokyo, Japan

相似试验